Optimal procedure in treatments of advanced ALK‑positive and ROS1‑positive non‑small cell lung cancers

04/2019

MUDr. Jana Krejčí; MUDr. Petr Opálka, CSc., MBA

Klinika pneumologie, 3. LF UK a Nemocnice Na Bulovce, Praha

SUMMARY

Lung cancer is one of the most common and most dangerous diseases. Currently, various treatments for non-small cell lung cancers are used, not only by histology but also by molecular genetic properties. A pre-treatment normative procedure should be performed with regard to the fact that ALK (anaplastic lymphoma kinase) translocation in all patients without magnificent histologies prior to treatment. ROS1 (ROS proto-oncogene 1) translocation and PD-L1 (programmed cell death 1 ligand 1) expression are also recommended. If you resort to being an ALK positivity that could be compromised. If ROS1 positive patients do not yet have any drugs in the Czech Republic, they will need to be covered by the rules that apply to ALK-positive patients, and there should also be an exception to the revision doctor.

Key words

non-small cell lung cancer, translocation ALK, translocation ROS1, crizotinib, ceritinib, alectinib, brigatinib